A complicated decision: Empiric antibiotics in children with complicated pneumonia
- PMID: 35504538
- DOI: 10.1002/jhm.2738
A complicated decision: Empiric antibiotics in children with complicated pneumonia
Comment on
-
Inpatient outcomes for children receiving empiric methicillin-resistant Staphylococcus aureus coverage for complicated pneumonia.J Hosp Med. 2022 Jan;17(1):36-41. doi: 10.1002/jhm.2736. Epub 2022 Jan 4. J Hosp Med. 2022. PMID: 35504578
References
REFERENCES
-
- Madhi F, Levy C, Morin L, et al. Change in bacterial causes of community‐acquired parapneumonic effusion and pleural empyema in children 6 years after 13‐valent pneumococcal conjugate vaccine implementation. J Pediatric Infect Dis Soc. 2019;8(5):474‐477. doi:10.1093/jpids/piy103
-
- Stankey CT, Spaulding AB, Doucette A, et al. Blood culture and pleural fluid culture yields in pediatric empyema patients: a retrospective review, 1996‐2016. Pediatr Infect Dis J. 2018;37(9):952‐954. doi:10.1097/INF.0000000000001940
-
- Wiese AD, Griffin MR, Zhu Y, et al. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era. Vaccine. 2016;34(50):6243‐6249. doi:10.1016/j.vaccine.2016.10.062
-
- Markham JL, Hackman S, Hall M, et al. Inpatient outcomes for children receiving empiric methicillin‐resistant Staphylococcus aureus coverage for complicated pneumonia. J Hosp Med. 2022;17(1):36‐41. doi:10.1002/jhm.2736
-
- Jones BE, Ying J, Stevens V, et al. Empirical anti‐MRSA vs standard antibiotic therapy and risk of 30‐day mortality in patients hospitalized for pneumonia. JAMA Intern Med. 2020;180(4):552‐560. doi:10.1001/jamainternmed.2019.7495
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical